论文部分内容阅读
目的探讨应用巴曲酶治疗急性缺血性脑卒中(CIS)患者的临床疗效。方法选取2014年1月至2015年6月期间黑龙江省医院收治的CIS患者64例作为研究对象,将其采用随机数字表法分为研究组与对照组,各32例。对照组患者应用常规治疗,研究组患者应用巴曲酶治疗,对比两组患者的治疗效果与安全性。结果研究组患者的治疗总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗前两组患者的MRS与NIHSS评分比较差异均无统计学意义(均P>0.05),治疗后24 h及7 d时,研究组患者MRS与NIHSS评分均显著低于对照组,差异均有统计学意义(均P<0.05);且治疗后研究组血浆纤维蛋白原(FIB)水平显著低于对照组,差异均有统计学意义(均P<0.05)。两组患者治疗期间均未见血、尿、便常规检查及肝肾功能检查异常,均未发生出血反应,无主诉或观察到不良反应发生。结论巴曲酶治疗CIS可提高临床疗效,能够快速、有效地改善患者的神经功能,且不良反应少,不增加出血风险,用药安全可靠。
Objective To investigate the clinical efficacy of batroxobin in the treatment of patients with acute ischemic stroke (CIS). Methods Sixty-four patients with CIS who were treated in Heilongjiang Provincial Hospital from January 2014 to June 2015 were selected as study subjects and divided into study group and control group with 32 cases in each group. Patients in the control group were treated with conventional therapy. Patients in the study group were treated with batroxobin. The therapeutic effect and safety of the two groups were compared. Results The total effective rate of study group was significantly higher than that of the control group (P <0.05). There was no significant difference between the two groups in MRS and NIHSS scores before treatment (all P> 0.05) The levels of MRS and NIHSS in the study group were significantly lower than those in the control group at 24 and 7 days after treatment (all P <0.05), and the levels of fibrinogen (FIB) in the study group were significantly higher Lower than the control group, the difference was statistically significant (P <0.05). No blood, urine, routine examination and abnormal liver and kidney function tests were found during the two groups. No bleeding reaction, no chief complaint or adverse reaction were observed. Conclusion Batroxobin treatment of CIS can improve the clinical efficacy, can quickly and effectively improve the patient’s neurological function, and less adverse reactions, does not increase the risk of bleeding, medication safe and reliable.